Cargando…
The enhanced antitumour response of pimozide combined with the IDO inhibitor L-MT in melanoma
Melanoma is one of the most fatal and therapy-resistant types of cancer; therefore, identifying novel therapeutic candidates to improve patient survival is an ongoing effort. Previous studies have revealed that pimozide is not sufficient to treat melanoma; therefore, enhancing the treatment is neces...
Autores principales: | Jia, Huijie, Ren, Wenjing, Feng, Yuchen, Wei, Tian, Guo, Mengmeng, Guo, Jing, Zhao, Jingjing, Song, Xiangfeng, Wang, Mingyong, Zhao, Tiesuo, Wang, Hui, Feng, Zhiwei, Tian, Zhongwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065445/ https://www.ncbi.nlm.nih.gov/pubmed/30015838 http://dx.doi.org/10.3892/ijo.2018.4473 |
Ejemplares similares
-
PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide
por: Zhao, Tiesuo, et al.
Publicado: (2019) -
Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo
por: Ge, Shushan, et al.
Publicado: (2020) -
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
por: Sioud, Mouldy, et al.
Publicado: (2016) -
An Overview of Antitumour Activity of Polysaccharides
por: Jin, Hongzhen, et al.
Publicado: (2022) -
Pimozide: An Old Wine in a New Bottle!
por: Naguy, Ahmed
Publicado: (2017)